CORE-ABR
Sales sheet Request a demo

Pathogen

Proteus mirabilis / vulgaris

Urease-producing Enterobacterales associated with complicated UTI, catheters and stones.

Also: P. mirabilis, P. vulgaris

Gram-negative bacteriaUTI panelWound panelGraded on the antibiogram

How CORE-ABR grades it

Intrinsic resistance applied: nitrofurantoin, the tetracyclines (including tigecycline) and the polymyxins. P. vulgaris additionally carries resistance to ampicillin, first-generation cephalosporins and cefuroxime. Removing nitrofurantoin for Proteus is one of the most common corrections a site-aware grid makes on a urinary report.

What the report shows for Proteus mirabilis / vulgaris

  • Detected or not detected, with Ct, limit of detection and cycles above LOD — see PCR reporting.
  • A short pathogen summary, including colonizer likelihood where it applies.
  • A graded column on the antibiogram, and therapy options by scenario on the P.A.C.T. report.
  • When not detected, it is still listed among targets tested.

Resistance genes CORE-ABR applies

When detected, each of these genes is applied to Proteus mirabilis / vulgaris only for the agents its mechanism defeats.

Class A beta-lactamase (CTX-M)Extended-spectrum beta-lactamase (ESBL) production6 organisms on panelClass C beta-lactamase (AmpC)AmpC cephalosporinase production5 organisms on panelqnrA / qnrBPlasmid-mediated quinolone resistance7 organisms on paneldfrA1 / dfrA5Trimethoprim resistance6 organisms on panelsul1 / sul2Sulfonamide resistance6 organisms on panel

Tagged

Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.